Medicine and Dentistry
Radiation Therapy
100%
Chemoradiotherapy
95%
Overall Survival
87%
Abdominal Cancer
62%
Rectum Cancer
62%
Neoplasm
49%
Malignant Neoplasm
48%
Anal Cancer
38%
Stomach Adenocarcinoma
35%
Adenocarcinoma
34%
Surgery
32%
Intensity Modulated Radiation Therapy
31%
Recurrent Disease
31%
Diseases
30%
Radiation Oncology
28%
Pancreas Cancer
27%
Chemoradiation Therapy
25%
Squamous Cell Carcinoma
25%
Cancer
24%
Pancreas Adenocarcinoma
22%
Metastatic Carcinoma
21%
Gastrectomy
21%
Pelvis
20%
Clinical Trial
18%
Survival Rate
16%
Computer Assisted Tomography
16%
Re-Irradiation
15%
Rectum Carcinoma
14%
Hazard Ratio
14%
Quality of Life
13%
Anal Canal
13%
Progression Free Survival
13%
Neoadjuvant Therapy
13%
Capecitabine
13%
Cisplatin
12%
Systemic Therapy
11%
Oncology
11%
Stereotactic Body Radiation Therapy
11%
Treatment Planning
10%
Proportional Hazards Model
10%
Colorectal Carcinoma
10%
Lymph Node
9%
Fluorouracil
9%
Gastroesophageal Junction
9%
Anus
9%
Cholangiocarcinoma
9%
Hodgkin's Lymphoma
9%
Acute Toxicity
9%
Phase II Trials
9%
Preoperative Chemotherapy
8%
Keyphrases
Overall Survival
51%
Chemoradiation
48%
Gastric Cancer
40%
Colorectal Cancer
36%
Gastric Adenocarcinoma
35%
Radiation Therapy
30%
Anal Cancer
28%
Chemotherapy
27%
Preoperative Chemoradiation
24%
Preoperative Therapy
24%
Radiotherapy
22%
Intensity-modulated Radiation Therapy
18%
Capecitabine
15%
Resectable Pancreatic Cancer
15%
Re-irradiation
14%
Confidence Interval
14%
Tumor
12%
Gastrectomy
12%
Preoperative Chemotherapy
12%
Hazard Ratio
12%
Pathological Complete Response
11%
Median Overall Survival
11%
Resection
11%
Acute Toxicity
11%
Anal Canal Carcinoma
11%
Gastroesophageal Adenocarcinoma
10%
Systemic Therapy
10%
Dose Escalation
10%
Pancreatic Ductal Adenocarcinoma
10%
Local Control
10%
Squamous Cell Carcinoma of the Anus
9%
Stereotactic Body Radiation Therapy
9%
5-fluorouracil (5-FU)
9%
Metastatic Disease
9%
Rectal Adenocarcinoma
9%
Locally Advanced Rectal Cancer
9%
Preoperative Chemoradiation Therapy
9%
Gastric Cancer Patients
9%
Hyperfractionated
8%
Gastrointestinal Malignancies
8%
Neoadjuvant Chemoradiotherapy (nCRT)
8%
Patient Selection
8%
Biologically Effective Dose
8%
Cisplatin
8%
Concurrent Chemotherapy
8%
Liver
8%
Radiation Treatment Planning
8%
Progression-free Survival
8%
Single Institution
8%
United States
7%